C0678594||structural
C0005539||bioengineered
C3667982||bovine
C0671062||Cathelicidin-5
C0556489||therapeutic activity
C0030956||Peptide
C0920472||drug discovery
C0520990||host-defense
C0030956||peptides
C0003232||antibiotic
C0334227||cancer cells
C0556489||therapeutic activity
C3667982||bovine
C0671062||cathelicidin-5
C0004611||bacteria
C0033739||protozoa
C0597032||tumor cells
C0596901||membrane
C0026377||conformational
C0671062||cathelicidin-5
C0005553||biophysical
C0936012||analysis
C0679083||atomistic simulations
C0814999||thymocytes
C0023418||leukemia
C0014834||E. coli
C0007603||cell-membranes
C0671062||cathelicidin-5
C0087111||intrusion
C0007603||membranes
C0243095||loss/gain-of-function
C0002776||analogues
C0079686||leucine-zipper
C0031453||phenylalanine
C0671062||cathelicidin-5
C1321418||antimicrobial
C0243095||anticancer activity
C2945560||hemolytic activity
C0596988||Targeted mutants
C0671062||cathelicidin-5
C1514568||N-terminal truncation
C0243095||loss-of-function
C0030956||peptide
C2825141||membranolytic
C2825141||non-membranolytic
C0025202||melanoma
C2986594||mouse model
C0671062||cathelicidin-5
C0278296||therapeutic application
C0671062||cathelicidin-5
C0002776||analogues